Please login to the form below

Not currently logged in
Email:
Password:

medicines value

This page shows the latest medicines value news and features for those working in and with pharma, biotech and healthcare.

Novartis sells off part of Sandoz portfolio

Novartis sells off part of Sandoz portfolio

Francis adds: “Sharpening our portfolio focus in the US allows us to devote more time and resources toward our strategy of bringing complex generics, value-added medicines and biosimilars to patients, ... creating higher value and opening up access to

Latest news

More from news
Approximately 2 fully matching, plus 131 partially matching documents found.

Latest Intelligence

  • Lonely planet: why there is dwindling value in pharma travelling alone Lonely planet: why there is dwindling value in pharma travelling alone

    As governments explore new ways of finding efficiencies in the public purse, many are introducing value-based models that reimburse medicines based on the outcomes they deliver. ... In the process, the focus on demonstrating value has now reached fever

  • Working with our healthcare system more closely is vital Working with our healthcare system more closely is vital

    The new scheme needs to be balanced to ensure that patients get the new medicines they need; deliver value for money for the NHS; and enable a thriving UK pharmaceutical sector ... that can continue to innovate in medicines and create jobs and value to

  • Adding value in emerging markets Adding value in emerging markets

    Branded generics offer something of value. When you think of generic medicines, you think low cost, high volume, little differentiation. ... Well, there are a number of ways to add value to off-patent medicines.

  • Biosimilars: what the future looks like Biosimilars: what the future looks like

    itself. We must build on the experience gained over the years of development and identify new opportunities where these medicines can truly add value. ... This also marked the culmination of many years of commitment and people’s personal journeys to

  • Righting pharma’s reputational wrongs Righting pharma’s reputational wrongs

    People say we have a powerful story to tell about the value of our medicines but are poor at getting the message across. ... These relationships are incredibly important and play a vital role in the development and delivery of new medicines.

More from intelligence
Approximately 1 fully matching, plus 36 partially matching documents found.

Latest appointments

  • Redx poaches AstraZeneca senior executive Redx poaches AstraZeneca senior executive

    grow this company into a very excising and meaningful entity that has the potential to create both important new medicines for patients and generate significant value for shareholders.".

  • Sanofi appoints Dr Yong-Jun Liu as head of research Sanofi appoints Dr Yong-Jun Liu as head of research

    In his new role, Dr Liu will be responsible for all of the Paris-based pharmaceutical company's research and will be tasked with delivering innovative and high-value medicines.

  • ABPI Scotland appoints Sandra Auld as director ABPI Scotland appoints Sandra Auld as director

    the access to and use of new and innovative medicines for Scottish patients. “ ... The ABPI Scotland team is fully committed to working with all of our stakeholders to support a common understanding and appreciation of the life-saving and

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • How to measure health behaviour change programmes

    The value outcome of medicines is still largely measured against healthcare systems or general societal outcomes. ... But the ways in which we measure patient benefits and value needs to be equally creative.

  • How will the NHS’s new medicines savings drive affect pharma?

    value medicines that can be easily bought over-the-counter, such as antihistamines and sun cream. ... In conclusion, the need for pharma to prove the value of its products has never been greater.

  • Packer Forbes collaborates with NHS Expert to strengthen growing team

    With today’ s emphasis on economic as well as clinical value, it recognises access barriers to medicines as a key challenge and works to uncover insightful understanding of the issues in

  • Value of Medicines

    Value of Medicines. By focusing on cost are we obscuring the true value of medicines? ... David Coleiro, Paula Lashley and John Grime take a look at how society values medicines, the role of health technology assessment (HTA) bodies like NICE, what value

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics